Hepatitis C News and Research

Latest Hepatitis C News and Research

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

NVHR supports IOM report on inadequate federal funding for chronic viral hepatitis

With today's release of a landmark study by the Institute of Medicine (IOM), Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C, finding that inadequate public-health resources are being allocated to national and local prevention, control, and surveillance programs, the National Viral Hepatitis Roundtable (NVHR) today renewed its call for the Administration, Congress, and the entire health care system to take immediate and decisive action to implement the report's key recommendations.

12 Jan 2010

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

Inhibitex, Inc. today announced that its collaborator, Pfizer, Inc., has initiated patient recruitment for 408-patient, randomized, double-blind Phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus (S. aureus) vaccine (SA3Ag) in healthy adults.

12 Jan 2010

Idenix Pharmaceuticals announces significant progress in HCV development programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced significant progress in three HCV programs

12 Jan 2010

Public awareness campaign needed to curb health threats posed by hepatitis B and hepatitis C

Stepped-up vaccination requirements, a boost in resources for prevention and treatment, and a public awareness campaign similar to the effort that dispelled the stigma of HIV/AIDS are needed to curb the health threats posed by hepatitis B and hepatitis C, says a new report from the Institute of Medicine.

12 Jan 2010

AASLD supports IOM study that recommends ways to reduce viral hepatitis B and C

The American Association for the Study of Liver Disease (AASLD) today reacted favorably to the release by they Institute of Medicine (IOM) of the report of "Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C." This landmark study evaluated the burden from viral hepatitis and current preventive and management practices and recommended ways to reduce new cases of hepatitis B and C and morbidity and mortality from chronic disease.

11 Jan 2010

Coalition will respond to IOM report on viral hepatitis and support CDC research and programs

In anticipation of the release of the Institute of Medicine (IOM) report on viral hepatitis, the CDC Foundation (the independent nonprofit partner of the Centers for Disease Control and Prevention), in partnership with CDC's Division of Viral Hepatitis, recently launched the Viral Hepatitis Action Coalition.

11 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

SeraCare Life Sciences launches new products to aid discovery and development of drugs and diagnostics

SeraCare Life Sciences, Inc. announced today that the Company has added five new, differentiated products to its portfolio to meet the needs of SeraCare’s growing customer base in the life sciences industry.

9 Jan 2010

AHF launches national cross country HIV testing tour in Oregon

AHF’s ‘Testing America’ Tour, a six month, 48 state national cross country HIV testing tour, will visit Portland, Oregon for a testing event in Pioneer Courthouse Square from 10am to 3pm Saturday January 9th during the city’s fourth annual health week.

9 Jan 2010

R. Palmer Beasley awarded Hepatitis B Foundation's Distinguished Scientist Award 2010

R. Palmer Beasley, M.D., Ashbel Smith Professor at The University of Texas School of Public Health, has been awarded the Hepatitis B Foundation's Distinguished Scientist Award 2010.

9 Jan 2010

MinuteClinic re-accredited and earns the Joint Commission's Gold Seal of Approval

MinuteClinic, the retail health care division of CVS Caremark (NYSE: CVS) and the pioneer and largest provider of retail-based medical clinics in the United States, has become the first retail clinic to be re-accredited and earn the Joint Commission's Gold Seal of Approval(TM) for consecutive evaluation periods by having demonstrated compliance with The Joint Commission's national standards for health care quality and safety.

9 Jan 2010

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy.

8 Jan 2010

ZymoGenetics announces pricing of public offering of 14,000,000 shares

ZymoGenetics, Inc. today announced that it has priced an underwritten public offering of 14,000,000 shares of its common stock at a price of $6.00 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $79,000,000.

8 Jan 2010

Life-saving therapeutic interventions possible with early detection of hepatitis C recurrence

A recent study by doctors from the Hospital Cl-nic in Barcelona, Spain determined that repeated liver stiffness measurements (LSM) in the first year following liver transplant (LT) could discriminate between slow and rapid "fibrosers" (patients with fibrosis stage of F2-F4 one year post LT).

6 Jan 2010

Quercetin may prevent hepatitis C infection; findings may lead to less toxic treatments

Researchers have identified two cellular proteins that are important factors in hepatitis C virus infection, a finding that may result in the approval of new and less toxic treatments for the disease, which can lead to liver cancer and cirrhosis.

6 Jan 2010

Increased coffee consumption linked to reduced hepatic fibrosis

Researchers from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) determined that patients with chronic hepatitis C virus (HCV) who consumed more than 308 mg of caffeine daily had milder liver fibrosis. The daily amount of caffeine intake found to be beneficial is equivalent to 2.25 cups of regular coffee.

5 Jan 2010

Children’s vaccination coverage rises substantially in U.S.

About three-quarters of U.S. children received recommended vaccinations in 2008, up from about half in 2000, reports a new study from the Centers for Disease Control and Prevention (CDC).

5 Jan 2010

Peginterferon alpha-2a yields better results in treating patients with chronic hepatitis C

In patients with chronic hepatitis C, treatment with peginterferon alpha-2a (PegIFNα2a) plus ribavirin (RBV) better suppresses the virus to undetectable levels in the blood than treatment with peginterferon alpha-2b (PegIFNα2b) plus RBV, according to two new head-to-head studies in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

5 Jan 2010

FDA grants Priority Review designation for InterMune's NDA for pirfenidone

InterMune, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review designation for the company's New Drug Application (NDA) for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

4 Jan 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

NVHR supports IOM report on inadequate federal funding for chronic viral hepatitis

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

Idenix Pharmaceuticals announces significant progress in HCV development programs

Public awareness campaign needed to curb health threats posed by hepatitis B and hepatitis C

AASLD supports IOM study that recommends ways to reduce viral hepatitis B and C

Coalition will respond to IOM report on viral hepatitis and support CDC research and programs

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

SeraCare Life Sciences launches new products to aid discovery and development of drugs and diagnostics

AHF launches national cross country HIV testing tour in Oregon

R. Palmer Beasley awarded Hepatitis B Foundation's Distinguished Scientist Award 2010

MinuteClinic re-accredited and earns the Joint Commission's Gold Seal of Approval

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

ZymoGenetics announces pricing of public offering of 14,000,000 shares

Life-saving therapeutic interventions possible with early detection of hepatitis C recurrence

Quercetin may prevent hepatitis C infection; findings may lead to less toxic treatments

Increased coffee consumption linked to reduced hepatic fibrosis

Children’s vaccination coverage rises substantially in U.S.

Peginterferon alpha-2a yields better results in treating patients with chronic hepatitis C

FDA grants Priority Review designation for InterMune's NDA for pirfenidone

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Hepatitis C News and Research

Latest Hepatitis C News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in